MASH is the most severe form of MASLD ... Liver cirrhosis has two basic stages. If you find out you have it, your doctor will tell you what stage you're in. Depending on how well your liver ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

However, where it fell short was with respect to the failure at week 36 with the phase 2b SYMMETRY study, which used EFX to treat compensated cirrhosis patients due to MASH stage F4 fibrosis.

About 20% of people with MASH can progress to late-stage liver scarring which is called cirrhosis. Approximately three million people in the United States are estimated to have MASH-related cirrhosis.

Once MASH progresses to cirrhosis, median survival is about five years, three times shorter than for patients with moderate, or mid-stage, MASH.

More than 50% of patients in each dose cohort also saw a 1-stage or greater improvement in fibrosis without worsening of MASH, a key secondary endpoint, compared to 33% of the placebo group.

The Phase 2 test of the Akero drug, efruxifermin (EFX), was designed with a main goal of showing improvement by one stage of fibrosis or more with no worsening of other measures of MASH after 96 ...

About 20% of people with MASH can progress to late-stage liver scarring which is called cirrhosis. Approximately three million people in the United States are estimated to have MASH-related cirrhosis.

Both MASH studies are currently enrolling patients ... MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in conjunction with diet and exercise.